AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31418811 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 2707
Study 29086490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (watching video lessons at home plus peer support group teleconferences)
Number of subjects: 338
Study 29086490 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 338
Study 25311914 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH treatment (100 µg)
Number of subjects: 33
Study 25311914 — intervention group
Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 33
Study 23108952 — intervention group
Group type: EXPERIMENTAL
Intervention: ECX (Epirubicin, Cisplatin, Capecitabine)
Number of subjects: 200
Study 23108952 — intervention group
Group type: COMPARATOR
Intervention: ECX-B (ECX with Bevacizumab)
Number of subjects: 200
Study 21614665 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 participants)
Number of subjects: 98
Study 21614665 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard training group (26 participants)
Number of subjects: 98
Study 21614665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtraining group (23 participants)
Number of subjects: 98
Study 19711607 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of 6% hydrogen peroxide/pyrophosphate whitening strips for five minutes on the facial and lingual surfaces of the mandibular teeth.
Number of subjects: 77
Study 19711607 — intervention group
Group type: COMPARATOR
Intervention: Regular brushing (brushing control).
Number of subjects: 77
Study 16925613 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 0
Study 16925613 — intervention group
Group type: COMPARATOR
Intervention: H. pylori eradication
Number of subjects: 0
Study 16925613 — intervention group
Group type: COMPARATOR
Intervention: H. pylori treatment
Number of subjects: 0
Study 15370776 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons For Living inventory (RFL)
Number of subjects: 506
Study 11253839 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose zidovudine (AZT) 1500 mg/day
Number of subjects: 46
Study 11253839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9250555 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Number of subjects: 16
Study 9250555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8055497 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 32
Study 8055497 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 32
Study 2883680 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 0
Study 2883680 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene
Number of subjects: 0
Study 30192260 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls incident reports analysis
Number of subjects: 493
Study 31533069 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg every 2 weeks or 75 mg every 2 weeks with possible increase to 150 mg at 12 weeks)
Number of subjects: 4975
Study 31533069 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4975
Study 31533069 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Ezetimibe (control)
Number of subjects: 4975
Study 28407338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily for 12 weeks
Number of subjects: 79
Study 28407338 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 79
Study 27647480 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide added to sitagliptin (ADD-ON, n=20)
Number of subjects: 40
Study 27647480 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin switched to repaglinide (SWITCH, n=20)
Number of subjects: 40
Study 27647480 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide added to sitagliptin (ADD-ON)
Number of subjects: 40
Study 27647480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ADD-ON)
Number of subjects: 40
Study 24368638 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 200
Study 24368638 — intervention group
Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 200
Study 24368638 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 200
Study 23377513 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% gel
Number of subjects: 42
Study 23377513 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin gel (1% clindamycin phosphate)
Number of subjects: 42
Study 23377513 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination gel (clindamycin phosphate 1.2% and tretinoin 0.025%)
Number of subjects: 42
Study 20650919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg kg(‐1) bolus then 2 mg kg(‐1) h(‐1) infusion)
Number of subjects: 40
Study 20650919 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 40
Study 20650919 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.75 mg kg(‐1) bolus then infusion 1 mg kg(‐1) h(‐1))
Number of subjects: 40
Study 20650919 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.5 mg kg(‐1) bolus and infusion 2 mg kg(‐1) h(‐1))
Number of subjects: 40
Study 20650919 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 mg kg(‐1) bolus and infusion 4 mg kg(‐1) h(‐1))
Number of subjects: 40
Study 18772216 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. midazolam 0.02 mg kg(‐1)
Number of subjects: 45
Study 18772216 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. midazolam 0.06 mg kg(‐1)
Number of subjects: 45
Study 18772216 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study 15812375 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal QRS score
Number of subjects: 128
Study 15812375 — intervention group
Group type: COMPARATOR
Intervention: ST-segment deviation
Number of subjects: 128
Study 12088299 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 0
Study 12088299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery and radiation therapy
Number of subjects: 0
Study 12088299 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant therapy based on pathologic risk factors
Number of subjects: 0
Study 12088299 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation in recurrent endometrial cancer after surgery alone
Number of subjects: 0
Study 12088299 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiation
Number of subjects: 0
Study 12088299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing prospective randomized trials
Number of subjects: 0
Study 11037367 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive-behavioural therapy (CBT)
Number of subjects: 20
Study 11037367 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 20
Study 8675164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic vascular exclusion (HVE)
Number of subjects: 15
Study 1676306 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg b.d.)
Number of subjects: 34
Study 1676306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 6357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 100 mg + APAP 650 mg
Number of subjects: 146
Study 6357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 400 mg + APAP 650 mg
Number of subjects: 146
Study 6357207 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 146
Study 6357207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 31269506 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA, 3.0 g/day)
Number of subjects: 88
Study 31269506 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EPA (1.5 g/day) and DHA (0.7 g/day)
Number of subjects: 88
Study 31269506 — intervention group
Group type: COMPARATOR
Intervention: Docosahexaenoic acid (DHA, 1.4 g/day)
Number of subjects: 88
Study 28735832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 19
Study 26677770 — intervention group
Group type: EXPERIMENTAL
Intervention: RECODE COPD management programme, implementation measured with PACIC and ACIC scales.
Number of subjects: 20
Study 26677770 — intervention group
Group type: EXPERIMENTAL
Intervention: RECODE COPD management programme, implementation measured with own scale and ACIC.
Number of subjects: 20
Study 22526572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal (alloderm) grafts
Number of subjects: 24
Study 22526572 — intervention group
Group type: COMPARATOR
Intervention: Silastic sheets implants
Number of subjects: 24
Study 22073579 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long acting beta2 agonist (LABA) and inhaled corticosteroids (ICS)
Number of subjects: 0
Study 22073579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium alone
Number of subjects: 0
Study 22073579 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocisteine (mucolytic and anti-oxidant agent)
Number of subjects: 0
Study 19253069 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based memory training intervention, involving teaching and practicing two memory strategies over three training sessions.
Number of subjects: 0
Study 19253069 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group, no intervention provided.
Number of subjects: 0
Study 17006377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 396
Study 17006377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 396
Study 11908552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (Neoral-Sandimmun, 3 mg/kg/day)
Number of subjects: 12
Study 11908552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10839074 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (30 to 50 mg/kg loading dose, followed by 70 to 100 mg/kg/24 hours)
Number of subjects: 83
Study 10839074 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (30 to 50 mg/kg loading dose, followed by 70 to 100 mg/kg/24 hours) plus intramuscular fentanyl citrate (1 microgram/kg)
Number of subjects: 83
Study 10839074 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic pain assessments by nurses
Number of subjects: 83
Study 8567509 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% galactose solution with [1‐13C]galactose tracer
Number of subjects: 8
Study 8567509 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% glucose solution with [U‐13C]glucose tracer
Number of subjects: 8
Study 2138049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (1.25 to 5.0 mg/day, single dose)
Number of subjects: 24
Study 2138049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 106432 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 18
Study 106432 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 18
Study 106432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6138066 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 47
Study 6138066 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 47
Study 6138066 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam 25 mg
Number of subjects: 47
Study 6138066 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (various doses)
Number of subjects: 47
Study 6138066 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (higher doses)
Number of subjects: 47
Study 30596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Number of subjects: 0
Study 30596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptan treatment (sumatriptan)
Number of subjects: 0
Study 30596910 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 29464748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40
Study 29464748 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy guidance
Number of subjects: 40
Study 27255243 — intervention group
Group type: EXPERIMENTAL
Intervention: New optical biometer (AL‐Scan)
Number of subjects: 121
Study 25238912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut group (30 g/d of mixed nuts for 6 weeks)
Number of subjects: 60
Study 25238912 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22348309 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroEclipse II breath‐activated nebulizer (BAN)
Number of subjects: 40
Study 22348309 — intervention group
Group type: COMPARATOR
Intervention: Continuous flow small‐volume nebulizer (SVN)
Number of subjects: 40
Study 20561643 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical nerve stimulation (20 sessions, 20 minutes each, 10 Hz)
Number of subjects: 37
Study 20561643 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasacral transcutaneous electrical nerve stimulation
Number of subjects: 37
Study 20561643 — intervention group
Group type: COMPARATOR
Intervention: Sham (superficial scapular electrical stimulation)
Number of subjects: 37
Study 17902041 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 15
Study 16521417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg/day
Number of subjects: 26
Study 16521417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11774098 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy with prednisone and cyclophosphamide (n = 18)
Number of subjects: 39
Study 11774098 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis in addition to immunosuppression (n = 21)
Number of subjects: 39
Study 10610077 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular moderate intensity physical activity
Number of subjects: 0
Study 10610077 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in omega-3 fatty acids
Number of subjects: 0
Study 10610077 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training or low fat diet
Number of subjects: 0
Study 10610077 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0
Study 10610077 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 0
Study 9150995 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of hot-spring gas for 15 days
Number of subjects: 63
Study 9150995 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin VUFB for 28 days
Number of subjects: 63
Study 9150995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Agapurin SPOFA) for 28 days
Number of subjects: 63
Study 1837974 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo‐Provera
Number of subjects: 653
Study 1837974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nur‐Isterate
Number of subjects: 653
Study 1837974 — intervention group
Group type: COMPARATOR
Intervention: Injectables (Depo‐Provera and Nur‐Isterate)
Number of subjects: 653
Study 1837974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti‐inflammatory and anti‐fibrinolytic agents
Number of subjects: 653
Study 7347353 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Number of subjects: 100
Study 7347353 — intervention group
Group type: COMPARATOR
Intervention: Upper gastrointestinal radiography
Number of subjects: 100
Study 7347353 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed endoscopist
Number of subjects: 100
Study 7347353 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninformed endoscopist
Number of subjects: 100
Study 30994197 — intervention group
Group type: EXPERIMENTAL
Intervention: Test (soft contact lens with positive spherical aberration, +SA)
Number of subjects: 109
Study 30994197 — intervention group
Group type: COMPARATOR
Intervention: Control (single-vision soft contact lens)
Number of subjects: 109
Study 27116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (familiar folk music and images of nature) during FB
Number of subjects: 60
Study 27116084 — intervention group
Group type: COMPARATOR
Intervention: Standard care during FB (Control group)
Number of subjects: 60
Study 26833219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Streitberger's needle, Real Streitberger's needle, Phantom acupuncture session
Number of subjects: 76
Study 26833219 — intervention group
Group type: COMPARATOR
Intervention: Park Sham device with real needle, Park Sham device with sham needle, no treatment session
Number of subjects: 76
Study 24889893 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri tablets (DSM 17938 and ATCC PTA 5289), 2 tablets daily for 3 months
Number of subjects: 36
Study 24889893 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets without live bacteria
Number of subjects: 36
Study 24889893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 22518014 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine
Number of subjects: 3819
Study 19176423 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-therapy
Number of subjects: 805
Study 19176423 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-meds
Number of subjects: 805
Study 19176423 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 805
Study 17161552 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal balloon (ERB)
Number of subjects: 48
Study 17161552 — intervention group
Group type: COMPARATOR
Intervention: No endorectal balloon (No-ERB)
Number of subjects: 48
Study 16356431 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra fluids (intravenous fluid supplementation for 8 hours and oral supplementation for the duration of phototherapy)
Number of subjects: 74
Study 16356431 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 16356431 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra fluids
Number of subjects: 74
Study 12189481 — intervention group
Group type: EXPERIMENTAL
Intervention: endoscopic pulse detector
Number of subjects: 40
Study 9449498 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (0.01 ml/kg, maximum 0.3 ml [0.3 mg])
Number of subjects: 17
Study 9449498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular epinephrine (0.3 mg from an autoinjector)
Number of subjects: 17
Study 10150837 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimetabolites as pharmacologic modulators of wound healing in conjunction with argon laser suture lysis and small‐incision phacoemulsification techniques
Number of subjects: 0
Study 10150837 — intervention group
Group type: EXPERIMENTAL
Intervention: Current trends in the management of coincident glaucoma and cataract
Number of subjects: 0
Study 10150837 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of antimetabolites in combined glaucoma surgery
Number of subjects: 0
Study 2212181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program with formal provider training and implementation feedback
Number of subjects: 4466
Study 2212181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program with videotaped provider training and no feedback
Number of subjects: 4466
Study 2212181 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 4466
Study 2212181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention program (all types)
Number of subjects: 4466
Study 619949 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide
Number of subjects: 25
Study 619949 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrhonium
Number of subjects: 25
Study 619949 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide and glycopyrrhonium (combination)
Number of subjects: 25
Study 619949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg in 10% solution or 0.8 g/kg in 20% solution)
Number of subjects: 25
Study 30259764 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetes
Number of subjects: 28771
Study 30259764 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-treated diabetes
Number of subjects: 28771
Study 30259764 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 28771
Study 26826263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 0
Study 26826263 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 0
Study 26268772 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% NovaMin and fluoride (ReNew™)
Number of subjects: 48
Study 26268772 — intervention group
Group type: COMPARATOR
Intervention: Over-the-counter fluoride toothpaste (Crest®)
Number of subjects: 48
Study 23739212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of sucrose
Number of subjects: 143
Study 23739212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of protein
Number of subjects: 143
Study 23739212 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake of lactose
Number of subjects: 143
Study 21704306 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behaviour therapy for eating disorders (CBT‐E)
Number of subjects: 149
Study 18359424 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram stain of endotracheal aspirates (EA) and bronchoalveolar lavages (BAL)
Number of subjects: 705
Study 16476913 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 29
Study 16476913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 29
Study 16476913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 14551476 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (n = 202)
Number of subjects: 3771